Automata builds an operating system for laboratories, combining modular robotic hardware, orchestration software, and unified data infrastructure to let scientists program experiments rather than robots. Its platform aims to close the gap between AI-driven computational biology and the manual workflows still common in wet labs, delivering higher experimental throughput, reproducibility, and resource efficiency. The company already serves five top pharmaceutical companies through repeat deployments and large-scale automation projects. New product work is focused on data and closed-loop experimentation capabilities that enable self-serve, AI-driven drug discovery. Automata plans to use fresh capital to scale global customer deployments and expand engineering, product, and customer-success teams. Headquartered in London, the company positions itself as the reference architecture for autonomous, software-defined labs in pharma, biotech, and advanced research.

Total raised

$142M

Funding rounds

4

Latest round

Series C

Latest activity

Jan 2026